Literature DB >> 1747224

Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure.

W E Fee1, J B Roberson, D R Goffinet.   

Abstract

Results are reported of transpalatal, transcervical, and transmaxillary resection in 15 patients with recurrent nasopharyngeal cancer after failure of primary radiotherapy. Seven patients treated for cure have been followed up for more than 3 years (mean, 55 months; range, 40 to 82 months), with three (43%) remaining free of disease. Two patients are living with local disease (59 and 40 months postoperatively), while two have died of their local and regional recurrence (40 and 17 months postoperatively). Two additional patients underwent nasopharyngectomy for palliation. One of these patients died of uncontrolled disease 12 months postoperatively; the other remains alive with disease 70 months after resection. Six patients have been followed up for less than 3 years (mean, 22.3 months; range, 16 to 32 months). Of this group, one (17%) is without evidence of disease, four are living with local disease (13, 16, 17, and 27 months postoperatively), and one has died of disease (13 months postoperatively). Recurrence (10 of 13 patients) has occurred an average of 8 months after surgery (range, 4 to 17 months). Complications include transient marginal mandibular nerve weakness (one), permanent cranial nerve paralysis (two), nasopharyngitis and/or osteomyelitis of the cervical vertebrae or base of skull requiring intravenous antibiotics (two), aspiration pneumonia (two), prolonged nasogastric tube feeding (two), and intraoperative thyroid storm (one). No cerbrospinal fluid leaks or perioperative deaths occurred. The long-term cure rate and disease-free interval of transpalatal nasopharyngectomy lead us to believe that this technique is probably only slightly better than reirradiation in the appropriately selected patient.

Entities:  

Mesh:

Year:  1991        PMID: 1747224     DOI: 10.1001/archotol.1991.01870230049006

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

1.  Resection of persistent nasopharyngeal carcinoma.

Authors:  E Yumoto; K Gyo; N Yanagihara
Journal:  Skull Base Surg       Date:  1994

Review 2.  Endoscopic endonasal skull base surgery: past, present and future.

Authors:  Paolo Castelnuovo; Iacopo Dallan; Paolo Battaglia; Maurizio Bignami
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-09       Impact factor: 2.503

3.  Combined transoral transnasal robotic-assisted nasopharyngectomy: a cadaveric feasibility study.

Authors:  Iacopo Dallan; Paolo Castelnuovo; Filippo Montevecchi; Paolo Battaglia; Niccolò Cerchiai; Veronica Seccia; Claudio Vicini
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-18       Impact factor: 2.503

4.  Endoscopic endonasal resection of sinonasal and skull base malignancies in children: feasibility and outcomes.

Authors:  Abdulaziz AlQahtani; Mario Turri-Zanoni; Iacopo Dallan; Paolo Battaglia; Paolo Castelnuovo
Journal:  Childs Nerv Syst       Date:  2012-08-10       Impact factor: 1.475

5.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

Review 6.  Current treatment options for recurrent nasopharyngeal cancer.

Authors:  Carlos Suárez; Juan P Rodrigo; Alessandra Rinaldo; Johannes A Langendijk; Ashok R Shaha; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-24       Impact factor: 2.503

Review 7.  Cancer of the nasopharynx: functional surgical salvage.

Authors:  William Ignace Wei
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

Review 8.  Endoscopic endonasal technique: treatment of paranasal and anterior skull base malignancies.

Authors:  Pornthep Kasemsiri; Daniel Monte Serrat Prevedello; Bradley Alan Otto; Matthew Old; Leo Ditzel Filho; Amin Bardai Kassam; Ricardo Luis Carrau
Journal:  Braz J Otorhinolaryngol       Date:  2013 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.